Irritable bowel syndrome with constipation (IBS-C) is a common condition that affects the digestive system (the gut). Symptoms may include stomach cramps, bloating and constipation. The exact cause is unknown, and IBS-C is often a lifelong condition. While there is no cure, dietary changes and the use of medication can often help control symptoms. IBS-C has been linked to issues of digestion, stress, and a family history of the condition. IBS-C affects approximately 7-21% of the population globally and is a significant health care burden impacting health and quality of life of affected individuals. Treatment of IBS-C is particularly challenging as symptoms fluctuate over time and are often recurrent and resistant to administered drugs.
Tenapanor is an oral drug under development for the treatment of IBS-C. It acts directly in the gut to reduce absorption of sodium. Sodium increases fluid in the gut, loosening stool, and alleviating constipation. If licensed, tenapanor may offer an additional treatment option for IBS-C by increasing intestinal fluid content, accelerating gastrointestinal (GI) motility, and providing relief from symptomatic pain and discomfort. By acting directly in the gut, tenapanor also has a potential advantage of having minimal side effects.
Selonsertib is an investigational oral small molecule inhibitor of ASK1, a protein that mediates inflammation, apoptosis (cell death) and fibrosis in settings of oxidative stress. Oxidative stress can be increased in many pathological conditions including liver diseases such as NASH. NASH currently has no effective treatment apart from lifestyle interventions. If licensed, selonsertib will offer a new treatment option for NASH as no effective pharmacological therapies currently exist.